Multiple Sclerosis

German 3-year real-world data shows ozanimod keeps RRMS relapses low, disability stable, and safety consistent in routine care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

The assistant professor of neurology and ophthalmology at NYU Grossman School of Medicine discussed findings presented at AAN 2026 on the use of optical coherence tomography in pediatric MS. [WATCH TIME: 8 minutes]

The registered nurse at the University of Miami and the president of the IOMSN shared their thoughts on the unique demands of nursing in neurology, with a particular focus on their experience in multiple sclerosis nursing. [WATCH TIME: 6 minutes]

William Kilgo, MD, and rising chief resident Ashley Nguyen, MD, discuss the evolving neurology residency Match process, offering guidance on competitiveness, interviews, program fit, and recruitment in the virtual era.

The FDA approval of ocrelizumab for pediatric RRMS expands access to a high-efficacy anti-CD20 therapy for children and adolescents with historically limited treatment options.

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.

Neurology News Network for the week ending April 18, 2026. [WATCH TIME: 5 minutes]

Jaime Imitola, MD, FAAN, FANA, professor of neurology and director of the UConn Comprehensive MS Center, discussed validation data on VISIBL-MS and its role in improving early MS recognition.

The approved neurofilament light chain test offers a minimally invasive approach to assessing neuroaxonal damage, with potential to complement MRI in routine multiple sclerosis care.

MOGAD Awareness Month highlights the evolution of myelin oligodendrocyte glycoprotein antibody–associated disease from a once-misclassified condition to a distinct neuroimmunologic disorder.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute talked about the role of research, patient empowerment, and expanding treatment options in multiple sclerosis. [WATCH TIME: 5 minutes]

A small case series published in JAMA Neurology found interstitial lung disease in 9% of long-term ocrelizumab-treated patients, with cases emerging after a mean of 10.5 years of therapy.

A neuroimmunology fellow at the Cleveland Clinic shared her experience attending the 2026 ACTRIMS Forum, specifically focusing on the late-breaking data presented in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute discussed the importance of early recognition of invisible symptoms in comprehensive multiple sclerosis care. [WATCH TIME: 9 minutes]

A neuroimmunology fellow at the Cleveland Clinic reflected on the 2026 ACTRIMS Forum, highlighting key takeaways in multiple sclerosis research presented in the program. [WATCH TIME: 6 minutes]

Constance V. Katsafanas, DO, director of the Neurology Residency Program at the Marcus Neuroscience Institute, highlighted the importance of individualized treatment strategies in multiple sclerosis.

The director of the Neurology Residency Program at the Marcus Neuroscience Institute detailed the importance of tailoring treatment to patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Apply for a $40,000 international MS research award honoring senior women scientists advancing care for women; submissions close June 12, 2026.

The assistant professor of medicine at the University of Toronto discussed population-level evidence suggesting MS may precede EBV infection in rare cases and its implications for disease pathogenesis and diagnosis.

The professor of neurology at Cleveland Clinic’s Mellen Center for MS provided thoughts on how radiologic biomarkers may help shape the next generation of multiple sclerosis clinical trials. [WATCH TIME: 3 minutes]